Raymond James Financial’s VanEck Pharmaceutical ETF PPH Stock Holding History

Raymond James Financial’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.09M	Sell	20,131 -4,976	-20%	-$530K	﹤0.01%	3332
2025 Q4	$2.59M	Buy	25,107 +931	+4%	+$90.6K	﹤0.01%	3072
2025 Q3	$2.18M	Buy	24,176 +1,759	+8%	+$154K	﹤0.01%	3116
2025 Q2	$1.97M	Buy	22,417 +2,363	+12%	+$205K	﹤0.01%	3092
2025 Q1	$1.83M	Buy	20,054 +4,721	+31%	+$425K	﹤0.01%	3051
2024 Q4	$1.32M	Buy	+15,333	New	+$1.39M	﹤0.01%	3260

Other funds holding PPH

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

BCIM

British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

ERSOT

Employees Retirement System of Texas Austin, Texas $11.4B AUM 21.6% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

JSAM

J. Safra Asset Management New York $2.17B AUM 29.66% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Avalon Trust Santa Fe, New Mexico $1.63B AUM 42.75% 1-Year Est. Return

Raymond James Financial's PPH Position: Q1 2026 in Review

Raymond James Financial reduced its VanEck Pharmaceutical ETF (PPH) stake by 20% in Q1 2026, selling an estimated $530K and leaving 20,131 shares worth $2.09M. The position accounts for ﹤0.01% of the portfolio, ranked #3332.

Raymond James Financial first reported a position in PPH in Q4 2024 and has held it in 6 quarters since. The position peaked at $2.59M in Q4 2025. 147 funds tracked by Wall St. Rank hold PPH as of Q1 2026.

Raymond James Financial held 20,131 shares of VanEck Pharmaceutical ETF worth $2.09M as of Q1 2026.
Raymond James Financial sold 4,976 VanEck Pharmaceutical ETF shares in Q1 2026, an estimated $530K.
VanEck Pharmaceutical ETF made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #3332 holding.
Raymond James Financial first reported a position in VanEck Pharmaceutical ETF in Q4 2024 and has held it in 6 quarters since.
Raymond James Financial's VanEck Pharmaceutical ETF position peaked at $2.59M in Q4 2025.
147 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.